CSOP Hang Seng Biotech(03174.HK) up 1.17%, ESMO opens in Madrid today
- CSOP Hang Seng Biotech stood at HK$3.460, up 1.17%, with turnover of HK$3.49 million.
- The ETF tracks the Hang Seng Biotech Index with HK$877 million in assets.
NewTimeSpace News: CSOP Hang Seng Biotech(03174.HK) traded higher in Hong Kong in the afternoon session. As of 13:07 HKT on October 23, 2026, the ETF stood at HK$3.460, up 1.17%, with turnover of HK$3.49 million, volume of 1.0386 million units and a turnover rate of 0.40%.
The ETF is managed by CSOP Asset Management Limited and tracks the Hang Seng Biotech Index, covering the 30 largest biotech companies listed in Hong Kong that are eligible for Stock Connect. As of the same time, the ETF had assets of HK$877 million, a net asset value of HK$3.413 per unit and a board lot of 100 shares.
On the news front, CNR reported that the 2026 Congress of the European Society for Medical Oncology (ESMO) runs from October 23 to 27. Separately, Gelonghui reported that China's NMPA approved Harbour BioMed's batoclimab injection for adults with AChR antibody-positive generalised myasthenia gravis, the first FcRn-targeted therapy fully developed in China.
Guojin Securities said in a research note that late October brings the year's densest catalyst window for innovative drugs, with about 30 Chinese studies selected as ESMO late-breaking abstracts, a record, five of which made the presidential sessions; combined with third-quarter earnings validation and outbound BD delivery, the sector sits at the intersection of three drivers.
- CSOP Biotech(03174.HK) down 2.50%, InnoCare-Lilly pact up to $3.25bn
- CSOP Hang Seng Biotech ETF (03174.HK) Rises 0.55% Intraday as Record 29 Chinese Studies Make ESMO Late-Breaker List
- CSOP Hang Seng Biotech ETF (03174.HK) Rises 1.80% Intraday as Hansoh Signs Roche ADC Deal with US$400 Million Upfront
- CSOP Biotech(03174.HK) up 3.22%, Hengrui Novo license up to $2.6bn
- CSOP Biotech(03174.HK) up 2.89%, AstraZeneca $2bn Akeso partner deal
